NCT01576887View on ClinicalTrials.gov

A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
End-Stage Renal DiseaseType 2 Diabetes Mellitus
Interventions
DRUG

Bardoxolone Methyl 20 mg

Oral, once daily

DRUG

Placebo

Oral, once daily

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT01576887 - A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis | Biotech Hunter | Biotech Hunter